Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Epanova® (Omefas) in Severe Hypertriglyceridemia

NCT01242527 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01242527
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01242527 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Epanova® (Omefas) in Severe Hypertriglyceridemia
Lead sponsor
AstraZeneca
Phase
Phase 2/3
Overall status
Completed
Start date
January 31, 2011
Completion date
April 30, 2012
Enrollment
399 (actual)
Sites
68

Conditions

As the registry lists them; a condition with its own page is linked.

severe hypertriglyceridemia